Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Enrico Vasile

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8482-6963; OpenAlex author ID A5082066847. Sources: ClinicalTrials.gov.

Their work

Papers
36 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 trial · 2016: 4 papers · 2017: 3 papers · 2018: none · 2019: 5 papers · 2020: 6 papers · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 36

  1. Pancreatic ductal adenocarcinoma and pancreatic surgery in the 21st century: triumphs, turning points, and unresolved challenges. Co-author DOI 10.1007/s13304-025-02502-9↗
  2. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  3. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  4. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  5. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  6. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Co-author DOI 10.3390/cancers15030900↗
  7. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  8. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Co-author DOI 10.1007/s13304-020-00883-7↗
  9. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
  10. Adjuvant Radiotherapy in Patients With Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature. Co-author DOI 10.21873/anticanres.15283↗
  11. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153738↗
  12. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers13164131↗
  13. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
  14. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
  15. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  16. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. Co-author DOI 10.3389/fonc.2020.00064↗
  17. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  18. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. Co-author DOI 10.3748/wjg.v26.i21.2792↗
  19. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  20. FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. Reply. Last author DOI 10.1056/nejmc1900712↗
  21. Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of … Co-author DOI 10.1200/jco.19.00127↗
  22. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Co-author DOI 10.2217/pgs-2018-0149↗
  23. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… Last author DOI 10.3390/cancers11070939↗
  24. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  25. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08297-z↗
  26. Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience. Co-author DOI 10.5301/tj.5000664↗
  27. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Last author DOI 10.1002/ijc.30125↗
  28. Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. Last author DOI 10.1038/bjc.2016.69↗
  29. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Last author DOI 10.2217/fon.16.16↗
  30. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
  31. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. Co-author DOI 10.1093/jnci/djt346↗
  32. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  33. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
  34. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0049145↗
  35. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. First author DOI 10.1093/annonc/mdq686↗
  36. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Co-author DOI 10.2217/pgs.11.109↗

Trials 1

  1. Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer Principal investigator NCT02355119↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caterina Vivaldi · 18 shared papers, 2016–2026 · strength 1.85
  2. Lorenzo Fornaro · 14 shared papers, 2016–2023 · strength 1.35
  3. Ugo Boggi · 10 shared papers, 2011–2026 · strength 0.90
  4. Elisa Giommoni · 6 shared papers, 2020–2026 · strength 0.86
  5. Michèle Milella · 7 shared papers, 2013–2025 · strength 0.73
  6. Mario Scartozzi · 5 shared papers, 2017–2026 · strength 0.69
  7. Michele Reni · 8 shared papers, 2011–2025 · strength 0.65
  8. Letizia Procaccio · 4 shared papers, 2023–2026 · strength 0.63
  9. Sara Lonardi · 4 shared papers, 2023–2026 · strength 0.63
  10. Guido Giordano · 4 shared papers, 2023–2026 · strength 0.63
  11. Giampaolo Tortora · 4 shared papers, 2023–2026 · strength 0.63
  12. Silvia Catanese · 7 shared papers, 2016–2021 · strength 0.62
  13. Niccola Funel · 10 shared papers, 2011–2021 · strength 0.61
  14. Emanuele F. Kauffmann · 4 shared papers, 2019–2026 · strength 0.59
  15. Francesca Bergamo · 3 shared papers, 2024–2026 · strength 0.51
  16. Mariacristina Di Marco · 3 shared papers, 2023–2026 · strength 0.48
  17. Monica Niger · 3 shared papers, 2023–2026 · strength 0.48
  18. Ferdinando De Vita · 3 shared papers, 2022–2026 · strength 0.47
  19. Ingrid Garajová · 4 shared papers, 2016–2025 · strength 0.45
  20. Roberto Bianco · 3 shared papers, 2020–2026 · strength 0.43
  21. Chiara Caparello · 6 shared papers, 2016–2020 · strength 0.43
  22. Marina Macchini · 3 shared papers, 2022–2025 · strength 0.41
  23. Giuseppe Aprile · 3 shared papers, 2017–2026 · strength 0.41
  24. Irene Pecora · 4 shared papers, 2019–2021 · strength 0.39
  25. Daniela Campani · 6 shared papers, 2011–2021 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.